In my mind, the receipt of these payment coding designations is equally important to the FDA approval of Septicyte Rapid since it facilitates the third party payers and makes the hospitals providing treatment more certain that they will receive reimbursement.
SeptiCyte® RAPID Receives ICD-10-PCS Code from the U.S. Centers for Medicare & Medicaid Services (CMS)
ICD-10-PCS code to provide accurate documentation of sepsis diagnosis for medical claims using SeptiCyte® RAPID
SEATTLE and BRISBANE, Australia, Sept. 6, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostics company focused on improving outcomes for suspected sepsis patients, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted an International Classification of diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) code for Immunexpress' host response molecular test for sepsis, SeptiCyte® RAPID. The diagnosis code is designated as XXE5X38.
ICD-10 is a system designed by the World Health Organization that is utilized worldwide by providers and payers to classify and code diagnoses and procedures for claims processing and reimbursement, and to track patient treatments and outcomes. In the United States, CMS has adopted this system to support the country's healthcare infrastructure. ICD-10-PCS codes are procedure code sets applicable to all healthcare settings.
"Assigning this ICD-10-PCS code signifies another milestone in the expanding adoption of SeptiCyte RAPID in U.S. healthcare systems as it provides coders with a classification for billing and claims reimbursement for sepsis," commented Rollie Carlson, Ph.D., Chief Executive Officer of Immunexpress. "Sepsis is an under-diagnosed and under-reported condition in hospitals, and this ICD-10-PCS code will help to ensure that use of our sepsis-detecting technology is more accurately documented in medical claims."